Yumanity Therapeutics Names Robertson as Chief Medical Officer
20 November 2019 - - US-based clinical stage company Yumanity Therapeutics has appointed Brigitte Robertson, M.D., as chief medical officer, the company said.
Dr. Robertson brings nearly two decades of clinical and regulatory experience in neurology and psychiatry to her role, most recently serving as the therapeutic area head of neuroscience global clinical development at Takeda (formerly Shire).
Prior to her career in the pharmaceutical industry, Dr. Robertson practiced medicine as a board-certified adult, child and adolescent psychiatrist and held a faculty position at Duke University.
Prior to her role at Yumanity, Dr. Robertson spent over eight years at Takeda (formerly Shire).
While at Shire, as a therapeutic area head, she successfully led a number of global development teams and was responsible for the disease area strategy and execution of Shire's neuropsychiatry portfolio, including programmes in status epilepticus, Dravet syndrome and ADHD (e.g. Buccolam, Carbetrol, Vyvanse, Mydayis and Intuniv).
Before joining Shire, Dr. Robertson held senior roles at Sunovion Pharmaceuticals in clinical development and experimental medicine, and at GlaxoSmithKline (NYSE: GSK) in the Center for Excellence in Drug Discovery.
Dr. Robertson is the author of numerous referenced articles in leading peer-reviewed journals and has served as a member on several consortia to advance biomarker development and novel trial endpoints.
Throughout her career, Dr. Robertson has worked extensively across common indications and orphan diseases, covering both early and late-stage initiatives in neurology and psychiatry.
Prior to her career in industry, Dr. Robertson held faculty positions at Duke University, CCP Children's Hospital in San Diego, and served in the military.
She earned her medical degree from the University of Health Sciences Georgia and later completed her residency training in psychiatry at the University of Colorado Health Sciences Center.
Robertson subsequently also completed a fellowship in child psychiatry and a post-doctoral neuro-psychiatry and neuroimaging research fellowship at the University of California in San Diego.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.
Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is focused on discovering disease-modifying therapies for patients with Parkinson's disease and related disorders, amyotrophic lateral sclerosis, and Alzheimer's disease.
Leveraging its proprietary discovery engine, Yumanity Therapeutics' innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.